Filtered By:
Drug: SGLT2 Inhibitors
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 230 results found since Jan 2013.
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease
CONCLUSIONS: Patients diagnosed with chronic kidney disease have markedly increased risk of cardiovascular events, including myocardial infarction, stroke, heart failure, and cardiovascular death. However, until recently, there were few cardiovascular outcome studies that targeted enrollment specifically to those patients. Certain drugs now have shown benefits to cardiovascular end points in this population.PMID:37029538 | DOI:10.1177/10600280231165774
Source: The Annals of Pharmacotherapy - April 8, 2023 Category: Drugs & Pharmacology Authors: Chris M Terpening Source Type: research
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a second-li...
Source: Cardiovascular Diabetology - March 13, 2023 Category: Cardiology Authors: Pei-Chien Tsai, Wei-Jung Chuang, Albert Min-Shan Ko, Jui-Shuan Chen, Cheng-Hsun Chiu, Chun-Han Chen and Yung-Hsin Yeh Tags: Research Source Type: research
SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
